Groups
Company Size (Fulltime employees)
Looking for
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

ResoTher Pharma ApS Denmark

ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin A1 as resolution therapy for diseases where neutrophil-driven inflammation plays a key pathological role. Our current focus is on cardiovascular disorders and inflammatory disorders with a large unmet medical need. Our lead asset is ready for clinical development in 2021 and expect to reach PoC in myocardial infarction within 3 years.
Website:
www.resotherpharma.com
Year of foundation
2016
Looking for
Please specify your partnering goal
Interested in Pharma collaborators focused on cardiology, vascular inflammation, stroke and who wish to acquire Asia rights
Funding Status
Funded to complete preclinical development, raising funds to cover phase I - phase II POC
Now raising (In USD)
5-15M
Headquartner in China
No
Plan in China
We seek: - equity investment of € 5-15M to fund our clinical development - a co-development agreement for our lead compound in STEMI or adjacent cardiovascular indications with the goal to divest China/Asia rights in the given indication.
Biotech/Pharma Category
Assets Information 1: Name|Description|Indications|Stage|IP countries
RTP-026|Peptide|STEMI|Phase I ready|NA
Lone Veng
CEO 
Functionality
Management

Wanbang Biopharmaceuticals (Group) Co., Ltd China

Wanbang Biopharmaceuticals (Wanbang Biopharma) is a core member of Shanghai Fosun PHARMACEUNCAL (group) Co., Ltd.(Fosun Pharma”, Stock code: 600196-SH,02196-HK).
Website:
Chinawanbang.com
Looking for
Headquartner in China
Yes
Biotech/Pharma Category
Service Description
Therapeutic products: Diabetes, anti-tumor, Chronic kidney disease, cardiovascular drug,etc.
Dr Di Simon
高级BD经理 

WPD Pharmaceuticals Canada

WPD has 8 novel drug candidates with 4 that are in clinical development stage and 4 in pre-clinical development. These drug candidates were researched at institutions including the Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

Alongside direct investment of $60 million, over $29 million of grant funding (total of $89 million USD) has gone towards the development of our robust drug development pipeline with a focus on melanoma, brain cancer, leukemia, and pancreatic cancer. Notably, these funds do not include $14 million USD in grants recently awarded to WPD Pharmaceuticals from The National Centre for Research and Development in Poland.

With a groundswell of multi-continental grant support and a diverse portfolio of breakthrough drug technologies, WPD Pharmaceuticals is now strategically positioned to enter the market with blockbuster potential.

Website:
https://www.wpdpharmaceuticals.com/about/overview/
Company Size (Fulltime employees)
11-50
Year of foundation
2017
Stock Market and Ticker/Symbol/Number
WCSE: BIO
Looking for
Please specify your partnering goal
We are looking for investors and partners for co-develop our product in China and co-develop partner product in EU.
Now raising (In USD)
between $ 3 million - $10 million
Headquartner in China
No
Plan in China
We are looking for investors and partners for co-develop our product in China and co-develop partner product in EU.
Biotech/Pharma Category
Investment Focus
Seeking funding to move from pre clinical stage to Phase 1/2 clinical trial and support co-development in EU
Mariusz Olejniczak
CEO 
Functionality
Management

华润双鹤药业 China

央企,从事药品研发,生产,销售,产品超过300个,2019年营业收入将近100亿元,共有400人的研发团队,全国分布19个生产基地,销售网络遍布全国各省,销售团队超过2500人。希望寻找高壁垒仿制药,高端技术平台,505b2,创新化药,生物药&生物类似物的合作机会,合作方式灵活。
Website:
www.dcpc.com
Looking for
Headquartner in China
Yes
Biotech/Pharma Category
Service Description
Therapeutic products
怡 李
BD经理